Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer.

Murahashi,K; Yashiro,M; Inoue,T; Nishimura,S; Matsuoka,T; Sawada,T; Sowa,M; Hirakawa-Ys Chung,K

doi:10.3892/ijo.13.6.1235

Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer.

Authors:
- K Murahashi
- M Yashiro
- T Inoue
- S Nishimura
- T Matsuoka
- T Sawada
- M Sowa
- K Hirakawa-Ys Chung
View Affiliations

Affiliations: First Department of Surgery, Osaka City University Medical School, Abeno-ku, Osaka 545-8585, Japan.
Published online on: December 1, 1998 https://doi.org/10.3892/ijo.13.6.1235
Pages: 1235-1275

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We examined the effect of Tranilast on the reduction of the administered dose of cisplatin using a scirrhous gastric cancer model. Scirrhous gastric cancer cell line, OCUM-2M, and gastric fibroblasts, NF-10, were used. The IC50 values of CDDP to OCUM-2M cells were decreased by Tranilast in vitro. The combination treatment with Tranilast and CDDP decreased the xenografted tumor size. The combination therapy decreased fibrosis and mitosis, and increased apoptosis. These findings suggest that Tranilast increased the CDDP response on scirrhous gastric cancer. The combination treatment with Tranilast and CDDP may be useful as a new therapy for scirrhous gastric carcinoma.